Search Results

South Korea's SEC Joins National R&D Project for Active Dose Distribution Control Radiotherapy Equipment

South Korean electron beam source technology company SEC announced on August 25 that it has been selected as a joint research institution for the world's best active dose distribution control radiotherapy machine R&D project, and will participate in the development of core technologies related to next-generation radiotherapy equipment. The project is a newly established task under the Global Flagship Medical Device R&D Program of the South Korean government's medical device R&D fund, with a duration of 6 years and 6 months, starting from July this year and planned to continue until December 2032. The total project budget is 35.2 billion KRW, of which 28 billion KRW is government funding. Radexel serves as the lead institution, with SEC participating as a joint research institution. Other participating organizations include the Korea Atomic Energy Research Institute, Korea Testing Laboratory...

2026-08-25

University of Missouri Receives $1 Million Grant to Research New FLASH Radiotherapy System

On August 11, researchers at the University of Missouri School of Medicine received a $1 million grant from the National Institutes of Health to study a new technology in cancer radiotherapy—the TheryQ FLASHKNiFE system. The project is funded through June 2027. A long-standing challenge in cancer treatment is how to kill tumor cells while protecting surrounding healthy tissue as much as possible. Existing radiotherapy can already achieve millimeter-level precision, but radiation damage and related side effects still limit the dose patients can safely receive. Unlike conventional approaches, FLASH radiotherapy does not primarily alter the direction of radiation beams, but instead delivers irradiation in an extremely short time at an ultra-high dose rate...

2026-08-12

Zhongji Flash e-Flash 200A Enters Innovative Medical Device Special Review Program

Recently, the public notice period for the review results of applications for the Innovative Medical Device Special Review Program by the Center for Medical Device Evaluation of the National Medical Products Administration has concluded. The ultra-high dose rate electron beam radiotherapy system (e-Flash 200A), independently developed by Zhongji Flash Medical Technology Co., Ltd., has officially entered the Innovative Medical Device Special Review Program. According to reports, the e-Flash 200A is China's first ultra-high dose rate electron beam FLASH radiotherapy device and had previously been included in the "Global New" green channel. Its entry into the Innovative Medical Device Special Review Program signifies further recognition of the product's technological innovation and clinical application value. The system is designed for superficial tumor radiothe...

2026-08-04